Holen Sie sich die Stockscreener-App
20.34
0.99%
0.20
Handel nachbörslich:
20.34
Schlusskurs vom Vortag:
$20.14
Offen:
$20.08
24-Stunden-Volumen:
1.42M
Relative Volume:
0.97
Marktkapitalisierung:
$1.55B
Einnahmen:
$288.00K
Nettoeinkommen (Verlust:
$-228.06M
KGV:
-4.1766
EPS:
-4.87
Netto-Cashflow:
$-168.82M
1W Leistung:
-20.89%
1M Leistung:
-18.57%
6M Leistung:
+51.23%
1J Leistung:
+28.09%
1-Tages-Spanne:
$19.73
$20.38
1-Wochen-Bereich:
$19.65
$27.20
52-Wochen-Spanne:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| VRDN | 20.34 | 1.55B | 288.00K | -228.06M | -168.82M | -4.87 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
What is HC Wainwright's Forecast for VRDN FY2024 Earnings? - MarketBeat
Viridian Therapeutics’ (VRDN) Buy Rating Reiterated at Needham & Company LLC - Defense World
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $34.00 - Defense World
FY2024 EPS Forecast for Viridian Therapeutics Cut by Analyst - Defense World
What is Lifesci Capital’s Estimate for VRDN FY2024 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for VRDN FY2024 Earnings? - Defense World
(VRDN) Trading Signals - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%Should You Sell? - MarketBeat
Perceptive Advisors LLC's Strategic Acquisition in Viridian Ther - GuruFocus.com
Paradigm Biocapital Advisors LP Increases Stake in Viridian Ther - GuruFocus.com
Wedbush Has Pessimistic Outlook of VRDN FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for VRDN Issued By Leerink Partnrs - MarketBeat
What is Lifesci Capital's Estimate for VRDN FY2024 Earnings? - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Viridian Therapeutics Inc (VRDN) Quarterly 10-Q Report - Quartzy
Q1 Earnings Estimate for VRDN Issued By Wedbush - MarketBeat
HC Wainwright Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
Viridian Therapeutics stock target upgraded, keeps buy on veligrotug outlook By Investing.com - Investing.com Canada
Viridian Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate - Simply Wall St
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses - TipRanks
Viridian Therapeutics Reports Third Quarter 2024 Financial Results - citybiz
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viridian Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - XM
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Viridian Therapeutics earnings missed by $0.09, revenue fell short of estimates - Investing.com UK
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighTime to Buy? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Grants 150K Stock Options to New Employees in Retention Push | VRDN Stock News - StockTitan
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Net Present Value Model: Viridian Therapeutics Inc’s Veligrotug - GlobalData
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
Analyst Expectations For Viridian Therapeutics's Future - Fidelity Investments
Needham & Company LLC Reaffirms Buy Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Position Boosted by Novo Holdings A S - MarketBeat
How To Trade (VRDN) - Stock Traders Daily
VRDN Factor-Based Stock Analysis - Nasdaq
Viridian Therapeutics' Superior Prospects Make It A Buy (NASDAQ:VRDN) - Seeking Alpha
Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results - Insider Monkey
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
SG Americas Securities LLC Has $374,000 Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
State Street Corp's Strategic Reduction in Viridian Therapeutics Inc - Yahoo Finance
Viridian Therapeutics (NASDAQ:VRDN) Hits New 52-Week HighTime to Buy? - MarketBeat
Viridian Therapeutics Inc (VRDN) stock analysis: A comprehensive overview - US Post News
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Millennium Management LLC - MarketBeat
Financial Snapshot: Analyzing Viridian Therapeutics Inc (VRDN)’s Key Ratio Metrics - The Dwinnex
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):